Optimi Health Corp. IPO: What You Need to Know

Curious about the "psychedelic renaissance"? You might have heard of Optimi Health Corp. They plan to list on the Nasdaq exchange. Let’s break down what they do so you can decide if they deserve your hard-earned money.

1. What do they actually do?

Optimi runs a high-tech lab and farm in British Columbia, Canada. They are closing their retail supplement business (which sold non-psychedelic mushrooms like Lion's Mane) to focus entirely on the medical side of the industry.

They grow natural magic mushrooms and produce synthetic MDMA under strict pharmaceutical quality controls. Instead of selling directly to patients, they act as a business-to-business supplier for global drug developers, researchers, and clinical trials.

2. How do they make money?

Optimi is in an early, high-spending startup phase. While they have started making some initial sales in Australia, they are currently operating at a heavy loss.

Last year, they brought in about C$426,000 (US$306,000) in revenue but lost C$3.7 million (US$2.7 million). This means their losses were nine times higher than their sales, highlighting just how expensive it is to run their specialized facilities.

The losses have continued into their most recent quarters. In late 2025, they lost another C$1.55 million (US$1.1 million) in just a three-month period.

Currently, the company has C$1.8 million in cash and inventory on hand, but they owe C$8.5 million in short-term bills due within the year. This leaves them with a C$6.7 million cash shortage. This gap raises serious doubts about their ability to stay in business without immediate funding, making the money raised from this IPO a vital lifeline to keep them afloat.

3. The "Shovel Seller" Strategy

Most psychedelic companies try to invent and patent brand-new drugs. This is an incredibly risky path that can cost hundreds of millions of dollars and take a decade to complete.

Optimi is taking a different approach, often called the "shovel seller" strategy. During a gold rush, the people selling shovels often make more reliable money than the prospectors looking for gold. Instead of inventing drugs, Optimi wants to supply the raw, medical-grade materials that everyone else needs for their research.

By selling directly to other businesses, they avoid massive drug development costs. Instead of relying on patents, they protect their business using proprietary recipes and the highly restrictive Canadian government licenses required to handle these controlled substances.

4. The Nasdaq Move & "Reverse Split"

Optimi wants to list on the Nasdaq under the ticker OPTH. Here are the key numbers you need to know:

• The Shares: They are offering 2,142,857 shares at an expected price of US$6.00 to US$8.00 each.
• The Cash: They expect to pocket about US$12.3 million after paying their IPO fees. They plan to use this money to pay off their immediate bills, boost production, and expand their operations.
• The "Reverse Split": To qualify for a Nasdaq listing, the company recently approved a 1-for-30 reverse stock split. Think of this like trading thirty $1 bills for one $30 bill. It doesn't change the actual value of the company or your percentage of ownership; it simply bumps the individual share price up to meet the exchange's minimum requirements.

5. What are the main risks?

• U.S. Roadblocks: Optimi cannot sell its products in the U.S. yet. Doing so will require FDA approval, and the DEA strictly limits imports of these substances with tight annual quotas.
• The Client Domino Effect: Because Optimi sells to other researchers, their success is tied to their customers' success. If a major client's clinical trial fails or they run out of money, Optimi loses a vital source of revenue.
• The License Lifeline: Their entire business relies on specialized permits from Health Canada. If they violate any regulations and lose these licenses, they will be forced to shut down.
• Less Transparency for Investors: Because Optimi is a Canadian company listing in the U.S. as a "foreign private issuer," they face fewer reporting rules. They use different accounting standards than U.S. companies and are not required to file standard U.S. quarterly financial reports.
• No Cash Payouts: The company does not pay dividends and has no plans to start. Any return on your investment will have to come entirely from the stock price going up.

The Bottom Line

Backed by the billionaire family behind the athletic brand Lululemon, Optimi is a direct bet on the infrastructure of the medical psychedelics industry. By focusing on manufacturing rather than drug discovery, they have carved out a unique niche. However, their severe cash shortage, heavy short-term debt, regulatory hurdles, and ongoing losses mean this is a high-risk, speculative investment. If you decide to invest, make sure it is with money you can afford to lose.